OHRI

Lumenix and The Ottawa Hospital Partner to Implement the Artificially Intelligent Monitoring System to Enhance Patient Care, Support Clinical Staff and Hospital Operations

Retrieved on: 
Tuesday, September 26, 2023
Civic, Partnership, Hand, OHRI, The Ottawa Hospital, Intelligence, Learning, Research, AIMS, Hospital, Patient safety, Nursing, Ottawa Hospital Research Institute, Artificial intelligence, Robotics, Health, Medical device

Lumenix, a leader in building technologies and artificial intelligence, is set to install its world-leading and clinically-validated Artificially Intelligent Monitoring System (AIMS) platform technology at the Ottawa Hospital Civic Campus in the fall of 2023.

Key Points: 
  • Lumenix, a leader in building technologies and artificial intelligence, is set to install its world-leading and clinically-validated Artificially Intelligent Monitoring System (AIMS) platform technology at the Ottawa Hospital Civic Campus in the fall of 2023.
  • "The partnership between Lumenix, The Ottawa Hospital and The Ottawa Hospital Research Institute exemplifies the potential of collaboration in driving meaningful advancements in patient care while identifying operating efficiencies to empower our clinical care workers."
  • This collaboration solidifies the commitment of Lumenix, TOH and OHRI to ethically usher in the future of artificial intelligence in healthcare.
  • For more information about Lumenix, please visit: www.lumenix.com or contact Lumenix at [email protected]
    For more information about AIMS, please visit: www.aimsplatform.i o or contact Lumenix at [email protected] .

Ottawa OBGYN becomes new president of the SOGC

Retrieved on: 
Friday, June 9, 2023
University, Obstetrics, OHRI, Society of Obstetricians and Gynaecologists of Canada, Birth, The Ottawa Hospital, CHEO, Research, ACSC, Public health, Publication, Johns Hopkins University, Adolescence, Gynaecology, Ottawa Hospital Research Institute, Mortality, Professional degrees of public health, Conference, University of Ottawa Heart Institute, Birth control

OTTAWA, June 09, 2023 (GLOBE NEWSWIRE) -- Today, a physician from Ottawa, Dr. Amanda Black became the new president of the Society of Obstetricians and Gynaecologists of Canada (SOGC) at their Annual Clinical Scientific Conference (ACSC 2023).

Key Points: 
  • OTTAWA, June 09, 2023 (GLOBE NEWSWIRE) -- Today, a physician from Ottawa, Dr. Amanda Black became the new president of the Society of Obstetricians and Gynaecologists of Canada (SOGC) at their Annual Clinical Scientific Conference (ACSC 2023).
  • Dr. Black is a Professor of Obstetrics and Gynecology at The University of Ottawa.
  • She holds appointments at The Ottawa Hospital and CHEO and is an Associate Scientist at the Ottawa Hospital Research Institute (OHRI).
  • Dr. Black holds the Dr. Elaine Jolly Chair in Women’s Health Research at The University of Ottawa.

Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors

Retrieved on: 
Thursday, March 9, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Swiss Cancer League, MD, Virology, McGill University, University School, The Ottawa Hospital, Oklahoma State University College of Agricultural Sciences and Natural Resources, Jennerex, Journal, CD8, Therapy, Euronext Paris, University of Ottawa Faculty of Medicine, Ottawa Hospital Research Institute, Research, School, OHRI, Medical Research Council, Potyvirus, Publication, New York University Grossman School of Medicine, National university, Agriculture Network Information Center, Clinical, Biochemistry, University, LICR, CTL, Immunotherapy, University of Lausanne, OV, Faculty, Doctor of Philosophy, Medical Research Council (United Kingdom), Épalinges, Ludwig Cancer Research, McMaster University, Pharmaceutical industry, Science, Medicine, Biology, Cancer, Nature

Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces the appointment of Dr. John C. Bell and Dr. Pedro Romero as key scientific advisors.

Key Points: 
  • Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces the appointment of Dr. John C. Bell and Dr. Pedro Romero as key scientific advisors.
  • “John and Pedro are world leaders in cancer immunotherapy, and will bring considerable expertise to Transgene,” said Hedi Ben Brahim, Transgene’s CEO.
  • He formed, and continues to lead, the Canadian Oncolytic Virus Consortium, a trans-Canadian, multidisciplinary group developing virus-based cancer therapeutics.
  • Pedro obtained his MD at the School of Medicine of the National University of Colombia in Bogota.

Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Thursday, December 8, 2022
Therapy, Malignancy, Breast cancer, Vinblastine, National Cancer Institute, Injection, Ipilimumab, Neoplasm, NCT, Intensity, Woman, Data analysis, CD4, Mastectomy, Cooperative research and development agreement, Necrosis, Risk, Development, Bristol Myers Squibb, The Ottawa Hospital, Oncology nursing, Pain, Cisplatin, Ottawa Hospital Research Institute, Clinical trial, Merck & Co., University, T helper cell, Immunosuppression, Pembrolizumab, NCI, Diffusion, NK, Merck Sharp & Dohme Federal Credit Union, Diagnosis, OHRI, Cancer, Annual general meeting, Merck, Breast, Tumor necrosis factor, Immune system, Surgeon, Ontario Institute for Cancer Research, Poster, Patient, SHAO, CRADA, Medicine, Cell death, WOO, Publication, Pharmaceutical industry, Medical imaging, Vaccine

WESTPORT, Conn., Dec. 8, 2022 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, first-in-class immune-based cancer therapies designed to kill tumors and increase immune system recognition of cancers, today presented new data from the INVINCIBLE study in a live Spotlight Session Poster Presentation at the San Antonio Breast Cancer Symposium (SABCS) Annual Meeting being held at the Henry B. Gonzalez Convention Center, San Antonio, TX, from December 6-10, 2022.

Key Points: 
  • INT230-6 demonstrated the ability to cause up to 100% necrosis of presurgical breast cancer tumors in the window period from diagnosis to surgery.
  • Adverse events were mostly grade 1 with expected pain at the breast injection site; there were very few systemic adverse effects.
  • There is a waiting period prior to surgery that can last for several weeks, which is a stressful time.
  • The technology uses a dispersion enhancer that can cause high levels of tumor cell death and necrosis in multiple breast cancer subtypes.